Baxter EBITDA Margin 2010-2024 | BAX
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Baxter (BAX) over the last 10 years. The current EBITDA margin for Baxter as of March 31, 2024 is .
| Baxter EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2024-03-31 | $14.89B | $1.81B | 12.15% |
| 2023-12-31 | $14.81B | $1.73B | 11.68% |
| 2023-09-30 | $14.52B | $1.65B | 11.37% |
| 2023-06-30 | $14.43B | $1.88B | 13.05% |
| 2023-03-31 | $14.31B | $2.19B | 15.32% |
| 2022-12-31 | $14.51B | $2.29B | 15.81% |
| 2022-09-30 | $13.79B | $1.96B | 14.24% |
| 2022-06-30 | $13.40B | $2.11B | 15.77% |
| 2022-03-31 | $12.91B | $2.15B | 16.68% |
| 2021-12-31 | $12.15B | $2.22B | 18.25% |
| 2021-09-30 | $12.45B | $2.59B | 20.81% |
| 2021-06-30 | $12.20B | $2.55B | 20.91% |
| 2021-03-31 | $11.82B | $2.46B | 20.78% |
| 2020-12-31 | $11.67B | $2.46B | 21.04% |
| 2020-09-30 | $11.53B | $2.58B | 22.39% |
| 2020-06-30 | $11.41B | $2.60B | 22.80% |
| 2020-03-31 | $11.53B | $2.63B | 22.77% |
| 2019-12-31 | $11.36B | $2.59B | 22.81% |
| 2019-09-30 | $11.14B | $2.42B | 21.70% |
| 2019-06-30 | $11.05B | $2.30B | 20.82% |
| 2019-03-31 | $11.06B | $2.31B | 20.85% |
| 2018-12-31 | $11.10B | $2.36B | 21.22% |
| 2018-09-30 | $11.08B | $2.26B | 20.40% |
| 2018-06-30 | $11.02B | $2.16B | 19.62% |
| 2018-03-31 | $10.79B | $2.12B | 19.61% |
| 2017-12-31 | $10.58B | $2.04B | 19.26% |
| 2017-09-30 | $10.43B | $2.07B | 19.80% |
| 2017-06-30 | $10.28B | $1.97B | 19.18% |
| 2017-03-31 | $10.26B | $1.72B | 16.71% |
| 2016-12-31 | $10.16B | $1.55B | 15.20% |
| 2016-09-30 | $10.12B | $1.39B | 13.68% |
| 2016-06-30 | $10.05B | $1.30B | 12.97% |
| 2016-03-31 | $9.94B | $1.31B | 13.14% |
| 2015-12-31 | $9.97B | $1.21B | 12.12% |
| 2015-09-30 | $10.15B | $1.26B | 12.36% |
| 2015-06-30 | $10.38B | $1.27B | 12.21% |
| 2015-03-31 | $12.06B | $1.90B | 15.78% |
| 2014-12-31 | $13.50B | $2.53B | 18.75% |
| 2014-09-30 | $15.03B | $2.75B | 18.28% |
| 2014-06-30 | $16.03B | $3.29B | 20.51% |
| 2014-03-31 | $15.55B | $3.39B | 21.79% |
| 2013-12-31 | $15.15B | $3.38B | 22.30% |
| 2013-09-30 | $14.33B | $3.47B | 24.23% |
| 2013-06-30 | $14.09B | $3.57B | 25.30% |
| 2013-03-31 | $14.00B | $3.51B | 25.09% |
| 2012-12-31 | $13.94B | $3.48B | 24.99% |
| 2012-09-30 | $14.03B | $3.57B | 25.47% |
| 2012-06-30 | $14.03B | $3.54B | 25.21% |
| 2012-03-31 | $14.00B | $3.58B | 25.58% |
| 2011-12-31 | $13.89B | $3.62B | 26.03% |
| 2011-09-30 | $13.80B | $3.53B | 25.56% |
| 2011-06-30 | $13.54B | $3.56B | 26.27% |
| 2011-03-31 | $13.20B | $3.43B | 25.95% |
| 2010-12-31 | $12.84B | $2.82B | 21.97% |
| 2010-09-30 | $12.82B | $3.02B | 23.60% |
| 2010-06-30 | $12.74B | $2.97B | 23.30% |
| 2010-03-31 | $12.67B | $3.00B | 23.70% |
| 2009-12-31 | $12.56B | $3.52B | 27.98% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $16.740B | $14.813B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $179.530B | 23.51 |
| Stryker (SYK) | United States | $127.352B | 30.50 |
| Boston Scientific (BSX) | United States | $112.306B | 35.77 |
| Medtronic (MDT) | Ireland | $99.209B | 14.85 |
| EssilorLuxottica (ESLOY) | France | $98.424B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $40.079B | 0.00 |
| Haleon (HLN) | United Kingdom | $38.036B | 27.77 |
| ResMed (RMD) | United States | $27.817B | 26.12 |
| Terumo (TRUMY) | Japan | $24.149B | 34.10 |
| Koninklijke Philips (PHG) | Netherlands | $22.914B | 18.19 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.863B | 13.97 |
| Insulet (PODD) | United States | $13.811B | 61.24 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.789B | 0.00 |
| Demant (WILYY) | Denmark | $9.175B | 0.00 |
| BellRing Brands (BRBR) | United States | $7.686B | 36.15 |
| Bio-Rad Laboratories (BIO) | United States | $7.632B | 24.96 |
| Lantheus Holdings (LNTH) | United States | $5.441B | 13.56 |
| Haemonetics (HAE) | United States | $4.232B | 20.87 |
| GN Store Nord (GNNDY) | Denmark | $4.129B | 23.18 |
| Perrigo (PRGO) | Ireland | $3.543B | 10.74 |
| Prestige Consumer Healthcare (PBH) | United States | $3.408B | 16.22 |
| Neogen (NEOG) | United States | $3.277B | 31.52 |
| ICU Medical (ICUI) | United States | $2.864B | 25.27 |
| TG Therapeutics (TGTX) | United States | $2.830B | 79.61 |
| Envista Holdings (NVST) | United States | $2.808B | 11.59 |
| Agios Pharmaceuticals (AGIO) | United States | $2.387B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.363B | 46.25 |
| QuidelOrtho (QDEL) | United States | $2.100B | 11.66 |
| LeMaitre Vascular (LMAT) | United States | $1.822B | 53.41 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.723B | 0.00 |
| Warby Parker (WRBY) | United States | $1.589B | 0.00 |
| InMode (INMD) | Israel | $1.462B | 7.77 |
| AdaptHealth (AHCO) | United States | $1.317B | 9.79 |
| Verano Holdings (VRNOF) | United States | $1.228B | 0.00 |
| AtriCure (ATRC) | United States | $1.065B | 0.00 |
| Owens & Minor (OMI) | United States | $1.013B | 8.83 |
| National Vision Holdings (EYE) | United States | $0.980B | 31.20 |
| BioLife Solutions (BLFS) | United States | $0.932B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.757B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.676B | 14.40 |
| PetIQ (PETQ) | United States | $0.672B | 21.72 |
| Evolus (EOLS) | United States | $0.667B | 0.00 |
| Surmodics (SRDX) | United States | $0.598B | 37.47 |
| VAREX IMAGING (VREX) | United States | $0.596B | 14.02 |
| Valneva SE (VALN) | France | $0.505B | 0.00 |
| ZimVie (ZIMV) | United States | $0.495B | 42.19 |
| Quanterix (QTRX) | United States | $0.487B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.477B | 0.00 |
| Biote (BTMD) | United States | $0.475B | 10.93 |
| Jin Medical (ZJYL) | China | $0.398B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.376B | 0.00 |
| Cerus (CERS) | United States | $0.314B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.302B | 9.71 |
| Zynex (ZYXI) | United States | $0.288B | 39.44 |
| MacroGenics (MGNX) | United States | $0.257B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.254B | 25.19 |
| Aurora Cannabis (ACB) | Canada | $0.247B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.239B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.233B | 14.69 |
| Omeros (OMER) | United States | $0.223B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.213B | 0.00 |
| High Tide (HITI) | Canada | $0.171B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.155B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.155B | 21.96 |
| Capricor Therapeutics (CAPR) | United States | $0.151B | 0.00 |
| Veru (VERU) | United States | $0.140B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.137B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.133B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.110B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.105B | 0.00 |
| Fonar (FONR) | United States | $0.101B | 10.19 |
| Brainsway (BWAY) | Israel | $0.099B | 0.00 |
| InterCure (INCR) | Israel | $0.093B | 15.77 |
| Cellectar Biosciences (CLRB) | United States | $0.085B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.068B | 4.43 |
| MariMed (MRMD) | United States | $0.065B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.060B | 0.00 |
| Safety Shot (SHOT) | United States | $0.060B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.051B | 0.00 |
| Modular Medical (MODD) | United States | $0.050B | 0.00 |
| Bright Green (BGXX) | United States | $0.050B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.048B | 0.00 |
| Apyx Medical (APYX) | United States | $0.046B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.045B | 0.00 |
| United-Guardian (UG) | United States | $0.043B | 15.52 |
| ImmuCell (ICCC) | United States | $0.032B | 0.00 |
| Exagen (XGN) | United States | $0.031B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.024B | 0.00 |
| Nephros (NEPH) | United States | $0.022B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Agape ATP (ATPC) | $0.015B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.012B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.000B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |